



Docket No.: V9661.0043

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Patent Application of: Mee Len Chye et al.

Application No.: 10/725,829

Confirmation No.: 7267

Filed: December 1, 2003

Art Unit: 1638

For: GENETICALLY MODIFIED PLANTS
EXPRESSING PROTEINASE INHIBITORS,
SAPIN2A OR SAPIN2B, AND METHODS
OF USE THEREOF FOR THE INHIBITION
OF TRYPSIN-AND CHYMOTRYPSIN-LIKE
ACTIVITIES

Examiner: A. R. Kubelik

New York, NY
December 14, 2005

STATEMENT UNDER 37 C.F.R. § 1.804(a) AND (b)

U.S. Patent and Trademark Office
220 20th Street S.
Customer Window
Crystal Plaza Two, Lobby, Room 1B03
Arlington, VA 22202

Dear Sir:

The undersigned hereby states that the plasmid vectors, pSa7 and pMLVHisA, were deposited with China Center for Type Culture Collection (CCTCC) under the Budapest Treaty on June 9, 2005 and July 25, 2005, respectively, and were accorded accession nos. CCTCC M 205062 and CCTCC M 205084, respectively. Copies of the certificates issued by the CCTCC in connection with the deposits were submitted to the Office on December 14, 2005. The undersigned further states that the deposited materials are biological materials specifically identified as pSa7 and


Application No.: 10/725,829

Docket No.: V9661.0043

pMLVHisA, respectively, in the above-identified application as filed and that said plasmid vectors will be irrevocably and without restriction or condition released to the public upon the issuance of a patent

Dated: April 12, 2006

Respectfully submitted,

By 
Charles E. Miller
Registration No.: 24,576
DICKSTEIN SHAPIRO MORIN &
OSHINSKY LLP
1177 Avenue of the Americas
New York, New York 10036-2714
(212) 835-1400
Attorney for Applicant

IY/CEM/mgs

Attachments